Positive Benefits: Nicotinamide Riboside (NR) Supplementation on Biomarkers Associated with Neurological Disorders

This randomized, placebo-controlled, crossover study administered 1,000mg/day of NR for six weeks. Plasma samples and extracellular vesicles enriched for neuronal origin (NEVs), were obtained from a previous study of 22 healthy middle-aged and older adults (Martens et al. 2018).


The decline in NAD+ in the brain that comes with aging contributes to cellular and metabolic dysfunction and can be implicated in age-associated neurological disorders. This clinical study demonstrates that orally administered NR can augment neuronal NAD+ levels and affect biomarkers related to neurodegeneration in humans.


Vreones et al., Aging Cell, December 2022. “Oral Nicotinamide Riboside Raises NAD+ and Lowers Biomarkers of Neurodegenerative Pathology in Plasma Extracellular Vesicles Enriched for Neuronal Origin.”


To evaluate if NR can augment neuronal NAD+ concentrations and impact inflammatory and insulin signaling in plasma-derived human NEVs.


  • NR supplementation significantly increased NAD+ in NEVs, suggesting an increase in neuronal NAD+ levels.
  • In those with an increase in NAD+, NR supplementation decreased NEV levels of Aβ42, and biomarkers pJNK and pERK1/2, which are involved in insulin resistance and neuroinflammatory pathways.
  • These findings support the ability of oral NR supplementation to augment neuronal NAD+ levels and modify biomarkers related to neurodegenerative pathology in humans.
  • In additional, NEVs offer a new blood-based window into monitoring the physiologic response of NR in the brain.

(Source: Chromadex)

Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE

Visit HPA-China’s Information Hub, HERE